了解个体眼压对拉坦前列素和替莫洛尔治疗的反应。

IF 1.9 4区 医学 Q2 OPHTHALMOLOGY
Jeremy C Reitinger, David M Reed, Cameron Peres, Shan Fan, Vikas Gulati, Arash Kazemi, Arthur J Sit, Sayoko E Moroi, Carol B Toris
{"title":"了解个体眼压对拉坦前列素和替莫洛尔治疗的反应。","authors":"Jeremy C Reitinger, David M Reed, Cameron Peres, Shan Fan, Vikas Gulati, Arash Kazemi, Arthur J Sit, Sayoko E Moroi, Carol B Toris","doi":"10.1089/jop.2024.0112","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network. <b><i>Methods:</i></b> In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests. <b><i>Results:</i></b> More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff (<i>p</i> < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs (<i>p</i> < 0.01). Among timolol nonresponders (<i>n</i> = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders (<i>n</i> = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response. <b><i>Conclusions:</i></b> Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"251-258"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.\",\"authors\":\"Jeremy C Reitinger, David M Reed, Cameron Peres, Shan Fan, Vikas Gulati, Arash Kazemi, Arthur J Sit, Sayoko E Moroi, Carol B Toris\",\"doi\":\"10.1089/jop.2024.0112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Purpose:</i></b> To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network. <b><i>Methods:</i></b> In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests. <b><i>Results:</i></b> More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff (<i>p</i> < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs (<i>p</i> < 0.01). Among timolol nonresponders (<i>n</i> = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders (<i>n</i> = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response. <b><i>Conclusions:</i></b> Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.</p>\",\"PeriodicalId\":16689,\"journal\":{\"name\":\"Journal of Ocular Pharmacology and Therapeutics\",\"volume\":\" \",\"pages\":\"251-258\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ocular Pharmacology and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/jop.2024.0112\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ocular Pharmacology and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jop.2024.0112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:确定健康志愿者对拉坦前列素和替洛尔的不同眼压(IOP)反应的原因,并作为眼动力学和工程网络的一部分生成对照组。方法:在这项多中心、随机、交叉研究(NCT01677507)中,106名健康受试者(212只眼睛)双眼接受拉坦前列素或替洛尔治疗7天,两次治疗之间有6周的洗脱期。在每次治疗的基线和第8天评估眼部生物测定、血压计和房水动力学(AHD)。受试者被分为有反应者和无反应者,使用眼压降低15%或10%的临界值。采用配对t检验分析治疗效果及相关性。结果:拉坦前列素(54%)的应答率高于替洛尔(27%)(p < 0.01)。在两种药物的两个截止点上,有反应者的平均基线IOP高于无反应者(p < 0.01)。在替马洛尔无应答者(n = 56)中,39%对双眼拉坦前列素有应答,20%对单眼有应答,41%对双眼无应答。在拉坦前列素无应答者(n = 31)中,13%对双眼噻莫洛尔有应答,13%对单眼有应答,74%对双眼无应答。拉坦前列素增加了巩膜流出,而替莫洛尔减少了水流量和流出设施。低基线的巩膜流出与拉坦前列素反应有关。结论:较高的基线IOP预示着两种药物的疗效更好。较高的基线巩膜流出量预示对拉坦前列素无反应。没有AHD差异与替洛尔反应有关。替马洛尔无应答者通常对拉坦前列素有应答,反之则不然。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.

Purpose: To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network. Methods: In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests. Results: More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff (p < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs (p < 0.01). Among timolol nonresponders (n = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders (n = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response. Conclusions: Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.60
自引率
4.30%
发文量
72
审稿时长
1 months
期刊介绍: Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信